lenalidomid grindeks 15 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 15 mg / 1 kapsula - lenalidomid
lenalidomid grindeks 25 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 25 mg / 1 kapsula - lenalidomid
lenalidomid grindeks 5 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 5 mg / 1 kapsula - lenalidomid
enteroporc coli ac
ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - prašiči - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:- clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6- clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins- clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.
lenalidomid alkaloid-int 25 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 25 mg / 1 kapsula - lenalidomid
lenalidomid grindeks 15 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 15 mg / 1 kapsula - lenalidomid
lenalidomid grindeks 25 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 25 mg / 1 kapsula - lenalidomid
lenalidomid grindeks 7,5 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 7,5 mg / 1 kapsula - lenalidomid
lenalidomid stada 25 mg trde kapsule
lenalidomid - kapsula, trda - lenalidomid 25 mg / 1 kapsula - lenalidomid
voraxaze
serb sas - glucarpidase - metabolic side effects of drugs and substances - vsi drugi terapevtski izdelki - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.